These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 12753731)

  • 1. Cost-savings from subsidized pro-active pharmacist interventions.
    Law S; Wu W
    J Pharm Pharm Sci; 2003; 6(1):84-94. PubMed ID: 12753731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a clinical pharmacist on cost saving and cost avoidance in drug therapy in an intensive care unit.
    Chuang LC; Sutton JD; Henderson GT
    Hosp Pharm; 1994 Mar; 29(3):215-8, 221. PubMed ID: 10132696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of adverse drug events and cost savings associated with PharmD interventions in an academic Level I trauma center: an evidence-based approach.
    Hamblin S; Rumbaugh K; Miller R
    J Trauma Acute Care Surg; 2012 Dec; 73(6):1484-90. PubMed ID: 23064610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the clinical and economic outcomes of pharmacy interventions in drug-related problems.
    Westerlund T; Marklund B
    J Clin Pharm Ther; 2009 Jun; 34(3):319-27. PubMed ID: 19646078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling costs and outcomes of expanded availability of emergency contraceptive use in British Columbia.
    Soon JA; Meckley LM; Levine M; Marciante KD; Fielding DW; Ensom MH
    Can J Clin Pharmacol; 2007; 14(3):e326-38. PubMed ID: 18180535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials.
    Smith PK; Datta SK; Muhlbaier LH; Samsa G; Nadel A; Lipscomb J
    Ann Thorac Surg; 2004 Feb; 77(2):635-42; discussion 642-3. PubMed ID: 14759451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Economic impact of pharmacist's interventions: illustration in a rheumatology ward].
    Coursier S; Bontemps H; Brantus JF; Allenet B
    J Pharm Belg; 2008 Dec; 63(4):103-9. PubMed ID: 19320133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using clinical interventions to cost-justify additional pharmacy staff.
    Catania HF; Catania PN
    Hosp Pharm; 1988 Jun; 23(6):544, 546-8. PubMed ID: 10312548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study on generic medicine substitution practices among community pharmacists in the State of Penang, Malaysia.
    Ping CC; Bahari MB; Hassali MA
    Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):82-9. PubMed ID: 17879323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease.
    Hassan Y; Al-Ramahi RJ; Aziz NA; Ghazali R
    Ann Pharmacother; 2009 Oct; 43(10):1598-605. PubMed ID: 19776297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can a disease self-management program reduce health care costs? The case of older women with heart disease.
    Wheeler JR; Janz NK; Dodge JA
    Med Care; 2003 Jun; 41(6):706-15. PubMed ID: 12773836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of a pharmacy resident on hospital length of stay and drug-related costs.
    Terceros Y; Chahine-Chakhtoura C; Malinowski JE; Rickley WF
    Ann Pharmacother; 2007 May; 41(5):742-8. PubMed ID: 17440008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of lifestyle intervention on health care costs: Improving Control with Activity and Nutrition (ICAN).
    Wolf AM; Siadaty M; Yaeger B; Conaway MR; Crowther JQ; Nadler JL; Bovbjerg VE
    J Am Diet Assoc; 2007 Aug; 107(8):1365-73. PubMed ID: 17659904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
    Burgess ED; Carides GW; Gerth WC; Marentette MA; Chabot I;
    Can J Cardiol; 2004 May; 20(6):613-8. PubMed ID: 15152291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacist monitoring of QTc interval-prolonging medications in critically ill medical patients: a pilot study.
    Ng TM; Bell AM; Hong C; Hara JM; Touchette DR; Danskey KN; Lindsay TT; Puumala SE
    Ann Pharmacother; 2008 Apr; 42(4):475-82. PubMed ID: 18319393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Not just in the East: progressively shorter lengths of stay for patients. Clinics save, family physicians sigh].
    Thomas A
    MMW Fortschr Med; 2006 Jan; 148(1-2):44-5. PubMed ID: 16610416
    [No Abstract]   [Full Text] [Related]  

  • 17. A prospective, randomized trial to assess the cost impact of pharmacist-initiated interventions.
    McMullin ST; Hennenfent JA; Ritchie DJ; Huey WY; Lonergan TP; Schaiff RA; Tonn ME; Bailey TC
    Arch Intern Med; 1999 Oct; 159(19):2306-9. PubMed ID: 10547170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical pharmacist in a multidisciplinary team in a paediatric department].
    Kjeldby C; Bjerre A; Refsum N
    Tidsskr Nor Laegeforen; 2009 Sep; 129(17):1746-9. PubMed ID: 19756055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost savings from use of emergency contraceptive pills in Australia.
    Trussell J; Calabretto H
    Aust N Z J Obstet Gynaecol; 2005 Aug; 45(4):308-11. PubMed ID: 16029298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the PIPC model on outcome measures of productivity and costs.
    Lengacher CA; Mabe PR; Heinemann D; VanCott ML; Swymer S; Kent K
    Nurs Econ; 1996; 14(4):205-12, 238. PubMed ID: 8826307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.